The Journal of Infectious Diseases · 2015 · 20 citations · 12 references
Viral PathogenesisImmunologyEbov Vp35Innate ImmunityAntiviral DrugImmune SystemVp35 ExpressionDouble-stranded Rna–stimulatedAntiviral Drug DevelopmentViral GeneticsHost-pathogen InteractionsInterferon βVirologyImmune FunctionEbola VirusMolecular VirologyEmerging Infectious DiseasesPathogenesisAntiviral ResponseAntiviral TherapyVirus-host InteractionMedicineViral Immunity
During Ebola virus (EBOV) infection, the type I interferon α/β (IFN-α/β) innate immune response is suppressed by EBOV viral protein 35 (VP35), a validated drug target. Identification of EBOV VP35 inhibitors requires a cellular system able to assess the VP35-based inhibitory functions of viral double-stranded RNA (dsRNA) IFN-β induction. We established a miniaturized luciferase gene reporter assay in A549 cells that measures IFN-β induction by viral dsRNA and is dose-dependently inhibited by VP35 expression. When compared to influenza A virus NS1 protein, EBOV VP35 showed improved inhibition of viral dsRNA-based IFN-β induction. This assay can be used to screen for EBOV VP35 inhibitors.
12